Al­ler­gan scores a PhI­II win with an ac­ne drug now head­ed to the FDA

Al­ler­gan is tee­ing up a new drug ap­pli­ca­tion for sare­cy­cline af­ter in­ves­ti­ga­tors re­port­ed that the ac­ne treat­ment scored promis­ing da­ta in two Phase III stud­ies.

High­light­ed in Al­ler­gan’s $AGN re­cent pipeline re­view as one of its late-stage drugs in the med­ical aes­thet­ics and der­ma­tol­ogy group, sare­cy­cline is a nar­row spec­trum an­tibi­ot­ic de­signed to elim­i­nate ac­ne. The drug is part­nered with Paratek $PRTK, which saw its shares shoot up 18% this morn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.